Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

[1]  T. Gille,et al.  Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. , 2023, The British journal of dermatology.

[2]  Jie Zheng,et al.  Evaluation of Dupilumab in Patients With Bullous Pemphigoid. , 2023, JAMA dermatology.

[3]  Furen Zhang,et al.  Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature. , 2023, International immunopharmacology.

[4]  K. Amber,et al.  Two patients with concomitant bullous pemphigoid and psoriasis successfully treated by IL‐23 inhibition , 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  A. Barzilai,et al.  Prevalence, Spectrum and Clinical Implications of Malignancies in Patients with Bullous Pemphigoid , 2023, Acta dermato-venereologica.

[6]  Zihua Chen,et al.  Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy , 2023, Frontiers in Immunology.

[7]  D. Didona,et al.  The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets , 2023, Frontiers in Medicine.

[8]  M. Wojtczak,et al.  Can Methotrexate Be Employed as Monotherapy for Bullous Pemphigoid? Analysis of Efficiency and Tolerance of Methotrexate Treatment in Patients with Bullous Pemphigoid , 2023, Journal of clinical medicine.

[9]  Bin Hu,et al.  Three cases of refractory bullous pemphigoid in the elderly treated successfully with ultra‐low‐dose rituximab , 2022, The Journal of dermatology.

[10]  M. Kirchhof,et al.  Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib , 2022, JAAD case reports.

[11]  A. Offidani,et al.  Bullous Pemphygoid and Novel Therapeutic Approaches , 2022, Biomedicines.

[12]  D. Zillikens,et al.  The relevance of complement in pemphigoid diseases: A critical appraisal , 2022, Frontiers in Immunology.

[13]  D. Murrell,et al.  Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review , 2022, JAAD international.

[14]  W. Li,et al.  Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib , 2022, Dermatologic therapy.

[15]  D. Murrell,et al.  A systematic review of side effects of steroid-sparing agents in bullous pemphigoid and pemphigus , 2022, JAAD International.

[16]  S. Keam.  Nemolizumab: First Approval , 2022, Drugs.

[17]  M. Fernández-Guarino,et al.  Low-dose rituximab for bullous pemphigoid. Protocol and single-centre experience. , 2022, Actas dermo-sifiliograficas.

[18]  Yao Hu,et al.  Dupilumab combined with low‐dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid , 2022, Dermatologic therapy.

[19]  Samantha R Pop,et al.  Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report , 2022, Dermatologic therapy.

[20]  Y. Teraki,et al.  Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T‐helper 2 cytokines , 2022, The Journal of dermatology.

[21]  D. Zillikens,et al.  Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial. , 2022, JAMA dermatology.

[22]  M. Afarideh,et al.  A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets , 2022, Journal of clinical medicine.

[23]  G. Girolomoni,et al.  A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab. , 2022, Dermatology online journal.

[24]  C. De Simone,et al.  Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: results from a multicenter study. , 2022, Journal of the American Academy of Dermatology.

[25]  L. Atzori,et al.  Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study , 2022, Frontiers in Medicine.

[26]  C. McCormack,et al.  Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report , 2022, The Australasian journal of dermatology.

[27]  R. Pampena,et al.  Pemphigus Vulgaris: Present and Future Therapeutic Strategies , 2022, Dermatology practical & conceptual.

[28]  Y. Nam,et al.  Successful induction treatment of bullous pemphigoid using reslizumab: a case report , 2021, Allergy, Asthma & Clinical Immunology.

[29]  Chao Ji,et al.  Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid , 2021, Frontiers in Immunology.

[30]  Lingyi Lu,et al.  Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis , 2021, The Journal of dermatology.

[31]  E. Bargagli,et al.  Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study , 2021, Arthritis & rheumatology.

[32]  Jie Zheng,et al.  BP230 IgE autoantibodies in topical‐steroid‐resistant bullous pemphigoid , 2021, The Journal of dermatology.

[33]  S. Yancey,et al.  Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2021, The Lancet. Respiratory medicine.

[34]  M. Gurel,et al.  Tissue eosinophil levels as a marker of disease severity in bullous pemphigoid , 2021, The Australasian journal of dermatology.

[35]  E. Schmidt,et al.  Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co‐morbidities , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[36]  D. Zillikens,et al.  COVID‐19 pandemic and autoimmune bullous diseases: a cross‐sectional study of the International Pemphigus and Pemphigoid Foundation , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[37]  D. Zillikens,et al.  Immunomodulator Galectin-9 is Increased in Blood and Skin of Patients with Bullous Pemphigoid , 2021, Acta dermato-venereologica.

[38]  L. Borradori,et al.  Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid , 2021, Frontiers in Immunology.

[39]  F. Jouen,et al.  Refractory bullous pemphigoid with IgE anti-BP230 and IgG anti-p200 antibodies successfully treated with omalizumab. , 2021, Annales de dermatologie et de venereologie.

[40]  D. Zillikens,et al.  Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[41]  Gang Wang,et al.  The role of T cells in pemphigus vulgaris and bullous pemphigoid. , 2020, Autoimmunity reviews.

[42]  P. Filipe,et al.  Dipeptidyl‐peptidase IV inhibitor‐associated bullous pemphigoid efficiently treated with omalizumab , 2020, Dermatologic therapy.

[43]  J. Silverberg,et al.  Association of bullous pemphigoid and comorbid health conditions: a case–control study , 2020, Archives of Dermatological Research.

[44]  Konstantinos I. Bougioukas,et al.  Total IgE, eosinophils, and interleukins 16, 17A, and 23 correlations in severe bullous pemphigoid and treatment implications , 2020, Dermatologic therapy.

[45]  P. Filipe,et al.  Emerging treatments for bullous pemphigoid , 2020, The Journal of dermatological treatment.

[46]  K. Motaparthi,et al.  Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps. , 2020, Clinics in dermatology.

[47]  M. Amagai,et al.  Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results , 2020, The British journal of dermatology.

[48]  B. King,et al.  Dupilumab as a Novel Therapy for Bullous Pemphigoid: A Multicenter Case Series. , 2020, Journal of the American Academy of Dermatology.

[49]  Hongzhong Jin,et al.  Factors associated with the activity and severity of bullous pemphigoid: a review , 2020, Annals of medicine.

[50]  G. Parry,et al.  Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in bullous pemphigoid. , 2019, The Journal of investigative dermatology.

[51]  N. Tovanabutra,et al.  Clinical outcome and safety of rituximab therapy for pemphigoid diseases. , 2019, Journal of the American Academy of Dermatology.

[52]  S. Pang,et al.  Diabetes Mellitus and Hyperglycemic Complications in Bullous Pemphigoid. , 2019, Journal of the American Academy of Dermatology.

[53]  H. Simon,et al.  Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo‐controlled, double‐blind phase 2 pilot study , 2019, Allergy.

[54]  N. Yawalkar,et al.  Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid , 2019, Front. Immunol..

[55]  D. Zillikens,et al.  Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. , 2019, JCI insight.

[56]  E. Berti,et al.  New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update , 2019, Frontiers in Immunology.

[57]  Yuan Liu,et al.  Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients. , 2019, Journal of the American Academy of Dermatology.

[58]  M. Seelen,et al.  Complement Activation in Autoimmune Bullous Dermatoses: A Comprehensive Review , 2019, Front. Immunol..

[59]  K. Tasanen,et al.  Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid , 2019, Front. Immunol..

[60]  Y. Tada,et al.  Secukinumab decreased circulating anti‐BP180‐NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid , 2019, The Journal of dermatology.

[61]  N. Alzueta,et al.  Bullous pemphigoid induced by ustekinumab: a case report , 2019, European journal of hospital pharmacy : science and practice.

[62]  D. Miyamoto,et al.  Bullous pemphigoid* , 2019, Anais brasileiros de dermatologia.

[63]  A. Larbi,et al.  B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid , 2019, Scientific Reports.

[64]  E. Antiga,et al.  Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab , 2019, European Journal of Dermatology.

[65]  P. Ortiz-Romero,et al.  Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report , 2019, Dermatologic therapy.

[66]  D. Leucuta,et al.  Complement-Activating Capacity of Autoantibodies Correlates With Disease Activity in Bullous Pemphigoid Patients , 2018, Front. Immunol..

[67]  M. Lapidoth,et al.  Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature , 2018, American Journal of Clinical Dermatology.

[68]  K. Amber,et al.  Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil‐derived neurotoxin on human keratinocytes , 2018, Experimental dermatology.

[69]  R. Eming,et al.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status , 2018, Drugs.

[70]  E. Papakonstantinou,et al.  Eosinophils are a Major Source of Interleukin-31 in Bullous Pemphigoid. , 2018, Acta dermato-venereologica.

[71]  Soo-Chan Kim,et al.  Circulating Eosinophil and Neutrophil Counts Correlate with Disease Severity in Bullous Pemphigoid , 2018, Annals of dermatology.

[72]  K. Kridin.  Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation , 2018, The British journal of dermatology.

[73]  A. Parodi,et al.  Immunoglobulin E and bullous pemphigoid , 2018, European Journal of Dermatology.

[74]  K. Kridin,et al.  Mortality in bullous pemphigoid: A systematic review and meta‐analysis of standardized mortality ratios , 2018, The Journal of dermatology.

[75]  A. Luster,et al.  The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin. , 2018, Seminars in immunology.

[76]  I. König,et al.  Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2 , 2018, Front. Immunol..

[77]  M. Gooderham,et al.  Dupilumab: A review of its use in the treatment of atopic dermatitis , 2018, Journal of the American Academy of Dermatology.

[78]  K. Eyerich,et al.  Immune response patterns in non‐communicable inflammatory skin diseases , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[79]  A. White,et al.  Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. , 2017, Clinical therapeutics.

[80]  P. Tighe,et al.  IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review , 2017, Archives of Dermatological Research.

[81]  G. Canonica,et al.  Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma , 2017, Front. Med..

[82]  T. Hashimoto,et al.  Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid , 2017, The British journal of dermatology.

[83]  T. Tsai,et al.  Development of bullous pemphigoid during secukinumab treatment for psoriasis , 2017, The Journal of dermatology.

[84]  F. Antonicelli,et al.  A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[85]  E. Deeks,et al.  Reslizumab in Eosinophilic Asthma: A Review , 2017, Drugs.

[86]  M. Rasmussen,et al.  Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population‐based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid , 2017, The British journal of dermatology.

[87]  E. Papakonstantinou,et al.  Increased Activity and Apoptosis of Eosinophils in Blister Fluids, Skin and Peripheral Blood of Patients with Bullous Pemphigoid. , 2017, Acta dermato-venereologica.

[88]  T. Kawakami,et al.  From IgE to Omalizumab , 2016, The Journal of Immunology.

[89]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[90]  M. Leverkus,et al.  Successful treatment of bullous pemphigoid with omalizumab as corticosteroid‐sparing agent: report of two cases and review of literature , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[91]  S. Tavakolpour.  Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus , 2016, Dermatologic therapy.

[92]  İ. Özcan,et al.  Bullous pemphigoid successfully treated with omalizumab , 2016, Indian journal of dermatology, venereology and leprology.

[93]  T. Cao,et al.  Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid. , 2016, Journal of dermatological science.

[94]  C. Hammers,et al.  Mechanisms of Disease: Pemphigus and Bullous Pemphigoid. , 2016, Annual review of pathology.

[95]  A. Markham.  Reslizumab: First Global Approval , 2016, Drugs.

[96]  D. Zillikens,et al.  IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases , 2016, Expert review of clinical immunology.

[97]  F. Antonicelli,et al.  Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome , 2015, Scientific Reports.

[98]  P. Coupé,et al.  Bullous pemphigoid during ustekinumab therapy , 2015, JAAD case reports.

[99]  Yung-Tsu Cho,et al.  First‐line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate‐to‐severe bullous pemphigoid , 2015, The British journal of dermatology.

[100]  R. Barker,et al.  T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid , 2015, Clinical and experimental immunology.

[101]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[102]  D. Zillikens,et al.  Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology , 2015, The British journal of dermatology.

[103]  F. Annunziato,et al.  The 3 major types of innate and adaptive cell-mediated effector immunity. , 2015, The Journal of allergy and clinical immunology.

[104]  R. Srikantha,et al.  Human Eosinophils Express the High Affinity IgE Receptor, FcεRI, in Bullous Pemphigoid , 2014, PloS one.

[105]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[106]  D. Woodley,et al.  Omalizumab therapy for bullous pemphigoid. , 2014, Journal of the American Academy of Dermatology.

[107]  Sarah L. Gaffen,et al.  The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing , 2014, Nature Reviews Immunology.

[108]  R. Streilein,et al.  Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. , 2013, The Journal of investigative dermatology.

[109]  Y. Kitajima,et al.  Bullous pemphigoid: role of complement and mechanisms for blister formation within the lamina lucida , 2013, Experimental dermatology.

[110]  H. Koga,et al.  A successful treatment with ustekinumab in a case of antilaminin‐γ1 pemphigoid associated with psoriasis , 2013, The British journal of dermatology.

[111]  D. Zillikens,et al.  Pemphigoid diseases , 2013, The Lancet.

[112]  Gautam Banerjee,et al.  The role of Th17/IL-17 on eosinophilic inflammation. , 2013, Journal of autoimmunity.

[113]  D. Woodley,et al.  Successful treatment of bullous pemphigoid with omalizumab. , 2012, Archives of dermatology.

[114]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[115]  B. Pulendran,et al.  New Paradigms in Type 2 Immunity , 2012, Science.

[116]  M. Hertl,et al.  IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses. , 2012, Clinical immunology.

[117]  Lin Ying Liu,et al.  Potent synergistic effect of IL-3 and TNF on matrix metalloproteinase 9 generation by human eosinophils. , 2012, Cytokine.

[118]  C. Bodemer,et al.  Successful management of severe infant bullous pemphigoid with omalizumab , 2012, The British journal of dermatology.

[119]  J. Fairley,et al.  Functional characterization of an IgE-class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180. , 2012, Hybridoma.

[120]  H. Maillard,et al.  Combined treatment with low‐dose methotrexate and initial short‐term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study , 2011, The British journal of dermatology.

[121]  M. Meurer,et al.  Up‐regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid , 2011, Clinical and experimental immunology.

[122]  D. Zillikens,et al.  Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice , 2011, Front. Immunol..

[123]  C. Benoist,et al.  Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis , 2010, Proceedings of the National Academy of Sciences.

[124]  G. Oostingh,et al.  IgE autoantibodies against the intracellular domain of BP180 , 2009, The British journal of dermatology.

[125]  Clifford M. Babbey,et al.  Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. , 2008, Molecular biology of the cell.

[126]  J. Bystryn.  Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid. , 2008, Archives of dermatology.

[127]  L. Diaz,et al.  Complement and cutaneous autoimmune blistering diseases , 2008, Immunologic research.

[128]  R. Watanabe,et al.  Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. , 2008, Journal of dermatological science.

[129]  R. Discipio,et al.  The role of the complement anaphylatoxins in the recruitment of eosinophils. , 2007, International immunopharmacology.

[130]  F. Batteux,et al.  Epidermolysis Bullosa Acquisita following Bullous Pemphigoid, Successfully Treated with the Anti-CD20 Monoclonal Antibody Rituximab , 2007, Dermatology.

[131]  D. Zillikens,et al.  The Pathophysiology of Bullous Pemphigoid , 2007, Clinical reviews in allergy & immunology.

[132]  Q. Hamid,et al.  Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines. , 2006, Clinical immunology.

[133]  Y. Iwakura,et al.  The IL-23/IL-17 axis in inflammation. , 2006, The Journal of clinical investigation.

[134]  M. Caproni,et al.  Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid. , 2002, Journal of dermatological science.

[135]  L. Vaillant,et al.  A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. , 2002, The New England journal of medicine.

[136]  P. Puddu,et al.  Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid. , 2002, European journal of dermatology : EJD.

[137]  K. Chung,et al.  Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. , 2001, American journal of respiratory and critical care medicine.

[138]  W. Pichler,et al.  Increased coexpression of eotaxin and interleukin 5 in bullous pemphigoid. , 2000, Acta dermato-venereologica.

[139]  M. Furue,et al.  Elevated levels of eotaxin and interleukin‐5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia , 2000, The British journal of dermatology.

[140]  E. Bröcker,et al.  Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. , 2000, Archives of dermatology.

[141]  P. Amerio,et al.  A Th2-like Cytokine Response is Involved in Bullous Pemphigoid. The Role of IL-4 and IL-5 in the Pathogenesis of the Disease , 1999, International journal of immunopathology and pharmacology.

[142]  C. Mackay,et al.  Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. , 1997, Science.

[143]  A. Parodi,et al.  Anti-230 kDa circulating IgE in bullous pemphigoid: relationship with disease activity. , 1997, Acta dermato-venereologica.

[144]  C. Anderson,et al.  The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[145]  J. Roujeau,et al.  Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. , 1996, Journal of the American Academy of Dermatology.

[146]  C. Kroegel,et al.  Mechanisms of human eosinophil activation by complement protein C5a and platelet‐activating factor: similar functional responses are accompanied by different morphologic alterations , 1995, Allergy.

[147]  D. Fivenson,et al.  Nicotinamide and tetracycline therapy of bullous pemphigoid. , 1994, Archives of dermatology.

[148]  T. Tomasi,et al.  Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternate pathway components and fibrin. , 1974, Clinical and experimental immunology.

[149]  R. Bergman,et al.  Mortality in Patients with Bullous Pemphigoid: A Retrospective Cohort Study, Systematic Review and Meta-analysis. , 2019, Acta dermato-venereologica.

[150]  M. John,et al.  IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid. , 2019, Clinical immunology.

[151]  D. Zillikens,et al.  Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity , 2017, JAMA dermatology.

[152]  T. Ruzicka,et al.  Bullous pemphigoid. , 2017, Autoimmunity reviews.

[153]  R. Schwartz,et al.  Enzyme-linked Immunoassay Index for Anti-NC16a IgG and IgE Auto-antibodies Correlates with Severity and Activity of Bullous Pemphigoid. , 2016, Acta dermato-venereologica.

[154]  M. Kodera,et al.  Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. , 2008, Archives of dermatology.

[155]  S. Shapiro,et al.  A critical role for neutrophil elastase in experimental bullous pemphigoid. , 2000, The Journal of clinical investigation.

[156]  A. Mastroianni,et al.  IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity , 1998, Archives of Dermatological Research.

[157]  H. Kita,et al.  In Vitro: Synergistic Effects of Platelet-activating Factor and Eosinophil-active Cytokines , 1997 .

[158]  F. Cambazard,et al.  [Cyclosporin in the treatment of bullous pemphigoid: preliminary study]. , 1986, Annales de dermatologie et de venereologie.